The Protein Myth: Our Obsession With Protein and How It Is Killing US

Houston Methodist

G. Davis

Health of Vegetarians and Vegans: Findings From EPIC-Oxford and Othe…

Physicians Committee for Responsible Medicine

T. J. Key

Weightloss in Menopause

Susan Brian

Is There a Future for HbA1c? (Moving Towards CGM: GMI and TIR)

Practical Ways to Achieve Targets in Diabetes Care

I. Hirsch

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

University of Colorado Department of Medicine

R. Johnson

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

Labs to Check on Semaglutide or Tirzepatide

Susan Brian

MAFLD: What Is It?

Houston Methodist

D. Victor

MetALD: What Is It, and How Do We Manage It?

Rush University Medical Center

L. Ritchie

Hypertension 2025: New Guidelines and Resistant Hypertension

University of Louisville

K. Ferdinand

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

Tirzepatide Updates

Diana Isaacs

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a Safer…

Ken Fujioka

Effects of Low Calorie and Alternative Sweeteners Across the Lifespa…

Keck School of Medicine of USC

M. Goran

Major Advancements in MASH Management

Rush University Medical Center

S. Janardhan

The Differences Between the Products of GLP1's and GLP/GIPs

Susan Brian

Metabolic Surgery vs. Pharmacotherapy for Treatment of Obesity

Practical Ways to Achieve Targets in Diabetes Care

S. Nissen

Revascularization for PAD Patients

Michigan Medicine - Podiatry

P. Henke

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Susan Brian